Active

Breaking point: causes and consequences of ‘centromere breakage’ in cancer development

Co-funded with:

ARC Fondation pour la recherche sur le cancer

Logo arc Fondation pour la recherche sur le cancer
Cancer types:

General cancer research

Project period:

Research institute:

Institut Curie

Award amount:

£216,500

Location:

France

Daniele Fachinetti Headshot
Researcher Dr Daniele Fachinetti

Dr Fachinetti and his team want to understand the link between cancer development and  defects in 'centromeres'- the glue holding together sister chromosomes inside our cells that carry our genes. They hope they can reveal possible new drug targets for cancer therapy. 

Hope for the future

Your cells are constantly dividing as part of keeping your body healthy. When this happens, one cell is divided into two daughter cells with the same number of chromosomes carrying the same DNA information. However, sometimes things go wrong, causing incorrect number of chromosomes and mutations in DNA, which is known to increase the risk of many types of cancer developing. 

Dr Fachinetti and his team believe that small structures in our cells called ‘centromeres’ are crucial for DNA instability. With your support, they will now find out more about the role of centromeres in cancer development and reveal new ways to target cancer with therapies.   

This project is co-funded with Fondation-ARC.

Daniele Fachinetti and Team
Meet the scientist

Since he was a child, Daniele was passionate about science. He loves to explore nature and animals. He likes to take pictures of the beauty of nature: from a small polyp in a coral reef to the majestic forest in Amazonia or ice field in the Arctics. 

The science

The DNA in your cells is found in small structures called chromosomes, which during cell division are made up of four arms glued together at the centre by ‘centromeres’. Defects in centromeres can cause the chromosome arms to break and reattach together in an abnormal way. This causes mutations to your genes and ‘genomic instability’, that can lead to the development of many cancer types.   

Dr Daniele Fachinetti and his team would like to understand why centromeres are hotspots for chromosome breakage and the role they play behind cancer development. The research team, alongside collaborators in France and the United States, will be using state-of-the-art technologies and techniques to reveal more than ever before about the role of centromeres in cell division.   

The team will be causing centromere breakage in human cells in the lab, so that they can better understand the conditions and mechanisms that lead to it.  They hope that by understanding these mechanisms, they will be able to identify new druggable targets with therapeutic potential for cancer treatment.  

I am grateful for the support of Curestarters who are allowing us to develop novel projects that in the future will impact the lives of cancer patients. 

Daniele Fachinetti Headshot
Dr Daniele Fachinetti

Related projects

Andres Hidalgo Headshot

Active Spain

Lung cancer

How do cancer cells modify white blood cells to help tumours grow?

Researchers want to help immunotherapy work for more cancer patients by understanding how cancers hijack our immune system and preventing this happening 

Researcher: Dr Andrés Hidalgo

Understanding how cancer cells modify white blood cells to help tumours grow
Andrew Beekman and Team

Active United Kingdom

General cancer research

Can we stop cancer becoming resistant to chemotherapy?

Chemotherapy can sometimes stop working, so this project is hoping to better understand why and find ways to give more, better options to cancer patients.

Researcher: Dr Andrew Beekman

Stopping cancer becoming resistant to chemotherapy
Tim Elliott and Team

Active United Kingdom

General cancer research

Can we predict which patients will respond to immunotherapy?

This project hopes to open up exciting possibilities for personalised cancer treatment by finding how to predict which patients will respond best to treatment.

Researcher: Professor Tim Elliott

Finding ways to predict which patients will respond to immunotherapy
Share this page